[A recombinant, humanized monoclonal antibody directed against CD22, a cell surface glycoprotein present on mature B-cells and on many types of malignant B-cells. After binding to CD22, epratuzumab's predominant antitumor activity appears to be mediated through antibody-dependent cellular cytotoxicity (ADCC). ( NCI )]
UMLS (NCI) C1120776hLL2
Humanized Anti-CD22 Monoclonal Antibody IgG1
- Amino Acid, Peptide, or Protein
- Pharmacologic Substance